Illumina (ILMN) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Illumina (NASDAQ: ILMN) recently:

• 11/12/2024 – Illumina had its price target raised by analysts at Stephens from $170.00 to $184.00. They now have an “overweight” rating on the stock.
• 11/12/2024 – Illumina had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $156.00 price target on the stock.
• 11/11/2024 – Illumina had its price target lowered by analysts at Piper Sandler from $195.00 to $185.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – Illumina had its price target raised by analysts at Robert W. Baird from $124.00 to $139.00. They now have a “neutral” rating on the stock.
• 11/5/2024 – Illumina had its price target raised by analysts at Royal Bank of Canada from $252.00 to $254.00. They now have an “outperform” rating on the stock.
• 11/5/2024 – Illumina had its price target raised by analysts at UBS Group AG from $133.00 to $145.00. They now have a “neutral” rating on the stock.
• 11/5/2024 – Illumina had its price target raised by analysts at JPMorgan Chase & Co. from $125.00 to $140.00. They now have a “neutral” rating on the stock.
• 11/5/2024 – Illumina had its price target raised by analysts at Canaccord Genuity Group Inc. from $130.00 to $145.00. They now have a “hold” rating on the stock.
• 11/5/2024 – Illumina had its price target raised by analysts at Barclays PLC from $135.00 to $145.00. They now have an “equal weight” rating on the stock.
• 11/5/2024 – Illumina had its price target raised by analysts at TD Cowen from $166.00 to $177.00. They now have a “buy” rating on the stock.
• 11/5/2024 – Illumina had its price target raised by analysts at Citigroup Inc. from $155.00 to $190.00. They now have a “buy” rating on the stock.
• 10/17/2024 – Illumina was upgraded by analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating. They now have a $180.00 price target on the stock.
• 10/17/2024 – Illumina had its price target raised by analysts at Leerink Partners from $160.00 to $200.00. They now have an “outperform” rating on the stock.
• 10/17/2024 – Illumina was upgraded by analysts at HSBC Holdings plc from a “hold” rating to a “buy” rating. They now have a $180.00 price target on the stock.
• 10/15/2024 – Illumina had its price target raised by analysts at Barclays PLC from $125.00 to $135.00. They now have an “equal weight” rating on the stock.
• 10/10/2024 – Illumina had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $252.00 price target on the stock.

Illumina Price Performance

Shares of ILMN traded down $1.45 during mid-day trading on Wednesday, reaching $146.17. 1,769,771 shares of the stock traded hands, compared to its average volume of 2,006,273. The firm has a fifty day moving average price of $138.84 and a 200 day moving average price of $123.95. The company has a market cap of $23.18 billion, a price-to-earnings ratio of -14.68 and a beta of 1.13. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 1 year low of $92.69 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current year.

Institutional Trading of Illumina

A number of hedge funds have recently made changes to their positions in ILMN. Vanguard Group Inc. lifted its stake in Illumina by 0.4% in the first quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after purchasing an additional 66,528 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Illumina by 7.2% during the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock valued at $317,267,000 after acquiring an additional 204,043 shares during the last quarter. Capital World Investors raised its stake in shares of Illumina by 41.1% during the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after acquiring an additional 801,814 shares during the last quarter. Primecap Management Co. CA raised its stake in shares of Illumina by 3.6% during the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after acquiring an additional 87,599 shares during the last quarter. Finally, GUARDCAP ASSET MANAGEMENT Ltd raised its stake in shares of Illumina by 1.1% during the first quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company’s stock valued at $284,097,000 after acquiring an additional 22,067 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.